Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

About this update from Telo Genomics Corp.

[{"type":"text","content":"Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple MyelomaToronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of telomeres, is pleased to announce that it has initiated a multiple myeloma (\"MM\") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland, OH. The samples are to be assessed and stratified between minimal residual disease (\"MRD\") patients that are active or in remission, in a clinical trial of the Company's TeloView MM-MRD assay. Telo Genomics announced its initial MRD trial in MM on February 22, 2024, in collaboration with McGill University/Jewish General Hospital, Montreal, Canada (NCT05530096). The new collaboration with Cleveland Clinic allows Telo to expand access and recruitment from a broader spectrum of patient groups, including patients receiving new CAR-T therapies that are more prevalent in the USA, and can contribute to expediting the validation of TeloView MM-MRD.MRD refers to the small number of remaining cancer cells post treatment. The TeloView MM-MRD test provides industry leading sensitivity for counting MRD cells, which is an established metric in assessing MRD. Critically, the TeloView MM-MRD test also offers the potential to profile the malignancy of individual cancer cells and stratify patients based on the aggressiveness of their remaining MRD. TeloView MM-MRD's proprietary approach of counting and profiling individual MRD cells has the potential to provide important, actionable information to clinicians and provide guidance in decision making, including; the extension of therapy, stopping therapy or resuming therapy, with the potential to improve clinical outcomes for MM patients post treatment. In North America, there are approximately 180,000 MM patients receiving treatment across the spectrum of different stages of the disease. Most of these patients could benefit from ongoing monitoring of treatment response using MRD assessment. Depending on the stage of the disease, patients may be monitored on a quarterly basis, leading to a total addressable market of approximately 800,000 tests per year.While the initial focu...

More updates from Telo Genomics Corp.